Decitabine reactivated pathways in platinum resistant ovarian cancer

Oncotarget

Volumn 5, Issue 11, 2014, Pages 3579-3589

  Fang, Fang ^a   Zuo, Qingyao ^b   Pilrose, Jay ^a   Wang, Yinu ^a   Shen, Changyu ^c   Li, Meng ^d   Wulfridge, Phillip ^a   Matei, Daniela ^e,f,g   Nephew, Kenneth P ^a,e,g  

^a Indiana University School of Medicine   (United States)

^b Beijing Jishuitan Hospital   (China)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f VA Roudebush Hospital   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemosensitization; Decitabine; DNA methylation; Gene expression; Pathway analysis; Platinum resistant ovarian cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABC TRANSPORTER; CANCER TESTIS ANTIGEN; CARBOPLATIN; CHEMOKINE RECEPTOR CCR6; CHORDIN; DNA METHYLTRANSFERASE 1; E1A ASSOCIATED P300 PROTEIN; G ANTIGEN 12B; GLYCOSAMINOGLYCAN; GLYCOSPHINGOLIPID; HOMEODOMAIN PROTEIN; INHIBIN B; INSULIN RECEPTOR SUBSTRATE; MELANOMA ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN INCONTINENTIA PIGMENTI 1; PROTEIN PATCHED 2; RETINOBLASTOMA BINDING PROTEIN 1; SCLEROPROTEIN; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; SYNOVIAL SARCOMA X BREAKPOINT 10; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR ANTIGEN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; WNT5B PROTEIN; X ANTIGEN FAMILY MEMBER 5; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE;

AHCYL2 GENE; AREA UNDER THE CURVE; ARTICLE; BIOINFORMATICS; BMP5 GENE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE; CHEK1 GENE; CHEMOSENSITIZATION; CHRD GENE; CLINICAL ARTICLE; CONTROLLED STUDY; DBF4 GENE; DNA METHYLATION; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; DRUG RESPONSE; ENOPH1 GENE; EP300 GENE; EXTRACELLULAR MATRIX; GAGE12B GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GMD5 GENE; HH GENE; HK1 GENE; HUMAN; HUMAN TISSUE; IHBA GENE; IPI GENE; LIPOGENESIS; LOW DRUG DOSE; MAGE GENE; MCM6 GENE; MULTIPLE CYCLE TREATMENT; OVARIAN CANCER CELL LINE; OVARY CANCER; POP7 GENE; PREDICTION; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PTCH2 GENE; RBL1I GENE; SIGNAL TRANSDUCTION; SMURF1 GENE; SSX10 GENE; TRANSLATION REGULATION; TUMOR BIOPSY; TUMOR GENE; UPREGULATION; XAGE5 GENE; ANALOGS AND DERIVATIVES; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENETICS; OVARIAN NEOPLASMS; TUMOR CELL LINE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CARBOPLATIN; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; OVARIAN NEOPLASMS;

EID: 84903532856     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1961     Document Type: Article

References (50)

1. Romero I and Bast RC, Jr. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012; 153(4):1593-1602.
2. Liu CM. Cancer of the ovary. The New England journal of medicine. 2005; 352(12):1268-1269; author reply 1268-1269.
3. Bast RC, Jr. Molecular approaches to personalizing management of ovarian cancer. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO. 2011; 22 Suppl 8:viii5-viii15.
4. Vaughan S, Coward JI, Bast RC, Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature reviews Cancer. 2011; 11(10):719-725.
5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31(15):1869-1883.
6. Balch C, Fang F, Matei DE, Huang TH and Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology. 2009; 150(9):4003-4011.
7. Balch C, Matei DE, Huang TH and Nephew KP. Role of epigenomics in ovarian and endometrial cancers. Epigenomics. 2010; 2(3):419-447.
8. Jones PA and Baylin SB. The epigenomics of cancer. Cell. 2007; 128(4):683-692.
9. Balch C, Yan P, Craft T, Young S, Skalnik DG, Huang TH and Nephew KP. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Molecular cancer therapeutics. 2005; 4(10):1505-1514.
10. Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S and Nephew KP. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC medical genomics. 2009; 2:34.
11. Zeller C, Dai W, Steele NL, Siddiq A, Walley AJ, Wilhelm-Benartzi CS, Rizzo S, van der Zee A, Plumb JA and Brown R. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene. 2012; 31(42):4567-4576.
12. Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, Li L, Kulesavage C, Snyder AJ, Nephew KP and Matei DE. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer. 2010; 116(17):4043-4053.
13. Matei D, Fang F, Shen C, Schilder J, Arnold A, Zeng Y, Berry WA, Huang T and Nephew KP. Epigenetic resensitization to platinum in ovarian cancer. Cancer research. 2012; 72(9):2197-2205.
14. Bonome T, Levine DA, Shih J, Randonovich M, Pise-Masison CA, Bogomolniy F, Ozbun L, Brady J, Barrett JC, Boyd J and Birrer MJ. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer research. 2008; 68(13):5478-5486.
15. Pereira GS, Brandao RM, Giuliatti S, Zago MA and Silva WA, Jr. Gene Class expression: analysis tool of Gene Ontology terms with gene expression data. Genetics and molecular research: GMR. 2006; 5(1):108-114.
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES and Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102(43):15545-15550.
17. Costa FF, Le Blanc K and Brodin B. (2007). Concise review: cancer/testis antigens, stem cells, and cancer.
18. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V and Mukherjee P. Role of hedgehog signaling in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(23):7659-7666.
19. Massague J and Chen YG. Controlling TGF-beta signaling. Genes & development. 2000; 14(6):627-644.
20. Ghosh AK and Varga J. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. Journal of cellular physiology. 2007; 213(3):663-671.
21. Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF and Warren EH. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. Journal of immunotherapy. 2012; 35(2):131-141.
22. Odunsi K, Matsuzaki J, James SR, Mhawech-Fauceglia P, Tsuji T, Miller A, Zhang W, Akers SN, Griffiths EA, Miliotto A, Beck A, Batt CA, Ritter G, Lele S, Gnjatic S and Karpf AR. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer. Cancer immunology research. 2014; 2(1):37-49.
23. Hekmat O, Munk S, Fogh L, Yadav R, Francavilla C, Horn H, Wurtz SO, Schrohl AS, Damsgaard B, Romer MU, Belling KC, Jensen NF, Gromova I, Bekker-Jensen DB, Moreira JM, Jensen LJ, et al. TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. Journal of proteome research. 2013; 12(9):4136-4151.
24. Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, Huang T, Yu MH and Lai HC. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Molecular cancer therapeutics. 2012; 11(8):1703-1712.
25. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(3):869-881.
26. Ying Y and Tao Q. Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers. Epigenetics: official journal of the DNA Methylation Society. 2009; 4(5):307-312.
27. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ and Widschwendter M. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. International journal of cancer Journal international du cancer. 2008; 123(3):725-729.
28. Matei DE and Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecologic oncology. 2010; 116(2):195-201.
29. Martin LP, Hamilton TC and Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(5):1291-1295.
30. Smyth I, Narang MA, Evans T, Heimann C, Nakamura Y, Chenevix-Trench G, Pietsch T, Wicking C and Wainwright BJ. Isolation and characterization of human patched 2 (PTCH2), a putative tumour suppressor gene inbasal cell carcinoma and medulloblastoma on chromosome 1p32. Human molecular genetics. 1999; 8(2):291-297.
31. Huang RL, Gu F, Kirma NB, Ruan J, Chen CL, Wang HC, Liao YP, Chang CC, Yu MH, Pilrose JM, Thompson IM, Huang HC, Huang TH, Lai HC and Nephew KP. Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics: official journal of the DNA Methylation Society. 2013; 8(6):624-634.
32. Ingham PW and McMahon AP. Hedgehog signaling in animal development: paradigms and principles. Genes & development. 2001; 15(23):3059-3087.
33. Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, Amsellem-Ouazana D and Bieche I. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. British journal of cancer. 2012; 106(6):1177-1186.
34. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY and Orsulic S. A Collagen-Remodeling Gene Signature Regulated by TGF-beta Signaling Is Associated with Metastasis and Poor Survival in Serous Ovarian Cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(3):711-723.
35. Kaye SB, Fehrenbacher L, Holloway R, Amit A, Karlan B, Slomovitz B, Sabbatini P, Fu L, Yauch RL, Chang I and Reddy JC. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(23):6509-6518.
36. Cao L, Shao M, Schilder J, Guise T, Mohammad KS and Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene. 2012; 31(20):2521-2534.
37. Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, Hamanishi J, Yamaguchi K, Kang HS, Okamoto T, Abiko K, Mori S, Murphy SK and Konishi I. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. International journal of cancer Journal international du cancer. 2012; 130(1):20-28.
38. Chan MW, Huang YW, Hartman-Frey C, Kuo CT, Deatherage D, Qin H, Cheng AS, Yan PS, Davuluri RV, Huang TH, Nephew KP and Lin HJ. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia. 2008; 10(9):908-919.
39. Saldova R, Dempsey E, Perez-Garay M, Marino K, Watson JA, Blanco-Fernandez A, Struwe WB, Harvey DJ, Madden SF, Peracaula R, McCann A and Rudd PM. 5-AZA-2'-deoxycytidine induced demethylation influences N-glycosylation of secreted glycoproteins in ovarian cancer. Epigenetics: official journal of the DNA Methylation Society. 2011; 6(11):1362-1372.
40. Dube DH and Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nature reviews Drug discovery. 2005; 4(6):477-488.
41. Januchowski R, Zawierucha P, Andrzejewska M, Rucinski M and Zabel M. Microarray-based detection and expression analysis of ABC and SLC transporters in drug-resistant ovarian cancer cell lines. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. 2013; 67(3):240-245.
42. Minamiya Y, Saito H, Takahashi N, Ito M, Toda H, Ono T, Konno H, Motoyama S and Ogawa J. Expression of the chemokine receptor CCR6 correlates with a favorable prognosis in patients with adenocarcinoma of the lung. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2011; 32(1):197-202.
43. Zhang J, Xu LG, Han KJ and Shu HB. Identification of a ZU5 and death domain-containing inhibitor of NF-kappaB. The Journal of biological chemistry. 2004; 279(17):17819-17825.
44. Hatzimichael E, Lo Nigro C, Lattanzio L, Syed N, Shah R, Dasoula A, Janczar K, Vivenza D, Monteverde M, Merlano M, Papoudou-Bai A, Bai M, Schmid P, Stebbing J, Bower M, Dyer MJ, et al. The collagen prolyl hydroxylases are novel transcriptionally silenced genes in lymphoma. British journal of cancer. 2012; 107(8):1423-1432.
45. Blanco P, Sargent CA, Boucher CA, Howell G, Ross M and Affara NA. A novel poly(A)-binding protein gene (PABPC5) maps to an X-specific subinterval in the Xq21.3/Yp11.2 homology block of the human sex chromosomes. Genomics. 2001; 74(1):1-11.
46. Geng Y, Ju Y, Ren F, Qiu Y, Tomita Y, Tomoeda M, Kishida M, Wang Y, Jin L, Su F, Wei C, Jia B, Li Y and Chang Z. Insulin Receptor Substrate 1/2 (IRS1/2) Regulates Wnt/beta-Catenin Signaling through Blocking Autophagic Degradation of Dishevelled2. The Journal of biological chemistry. 2014; 289(16):11230-11241.
47. Tsuruzoe K, Emkey R, Kriauciunas KM, Ueki K and Kahn CR. Insulin receptor substrate 3 (IRS-3) and IRS-4 impair IRS-1-and IRS-2-mediated signaling. Molecular and cellular biology. 2001; 21(1):26-38.
48. Yen HW, Jakimiuk AJ, Munir I and Magoffin DA. Selective alterations in insulin receptor substrates-1,-2 and-4 in theca but not granulosa cells from polycystic ovaries. Molecular human reproduction. 2004; 10(7):473-479.
49. Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD and Landen CN. Smoothened antagonists reverse taxane resistance in ovarian cancer. Molecular cancer therapeutics. 2012; 11(7):1587-1597.
50. Bapat SA, Jin V, Berry N, Balch C, Sharma N, Kurrey N, Zhang S, Fang F, Lan X, Li M, Kennedy B, Bigsby RM, Huang TH and Nephew KP. Multivalent epigenetic marks confer microenvironment-responsive epigenetic plasticity to ovarian cancer cells. Epigenetics: official journal of the DNA Methylation Society. 2010; 5(8):716-729.